Starling Oncology (STLNW) Cash from Financing Activities (2020 - 2026)
Starling Oncology's (STLNW) quarterly Cash from Financing Activities came in at -$218000.0 in Q2 2026, down 111.11% on a YoY basis from $2.0 million in Q2 2025, and down 678.57% quarter-over-quarter from -$28000.0 in Q1 2026.
Powered by 
Analysis
Starling Oncology (STLNW) Cash from Financing Activities (2020 - 2026) Analysis & Trends
Starling Oncology (STLNW) has reported Cash from Financing Activities for 7 consecutive years, with -$218000.0 the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Cash from Financing Activities fell 111.11% year-over-year to -$218000.0; the trailing twelve-month figure through Jun 2026 stood at $14.1 million (up 542.46% YoY), and the FY2025 full-year result was $11.6 million, up 430.96% from the prior year.
- Cash from Financing Activities fell to -$218000.0 in Q2 2026 per STLNW's latest filing, from -$28000.0 in the prior quarter.
- Across five years, Cash from Financing Activities topped out at $105.4 million in Q3 2022 and bottomed at -$10.7 million in Q2 2022.
- Historically, Cash from Financing Activities has averaged $5.2 million across 5 years, with a median of -$801500.0 in 2022.
- The sharpest annual moves came in 2022 and 2025: Cash from Financing Activities jumped 1317537.5% in 2022, then sank 405.33% in 2025.
- Over 5 years, Cash from Financing Activities stood at -$847000.0 in 2022, then sank by 110.27% to -$1.8 million in 2023, then jumped by 90.79% to -$164000.0 in 2024, then soared by 2376.83% to $3.7 million in 2025, then slumped by 105.84% to -$218000.0 in 2026.
- According to Business Quant data, Cash from Financing Activities over the past three periods registered -$218000.0, -$28000.0, and $3.7 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Davita | 11.90 Bn | 11.21 Bn | 1.16 Bn | -270.19 Mn |
| 2 | RadNet | 5.52 Bn | 4.79 Bn | 88.08 Mn | 240.22 Mn |
| 3 | Fresenius Medical Care AG | 4.79 Bn | 4.09 Bn | 1.52 Bn | -894.48 Mn |
| 4 | Concentra Group Holdings Parent | 4.28 Bn | 4.12 Bn | 192.10 Mn | -24.67 Mn |
| 5 | Privia Health | 2.57 Bn | 2.16 Bn | - | 3.04 Mn |
| 6 | Pediatrix Medical | 2.15 Bn | 1.74 Bn | - | -48.24 Mn |
| 7 | Progyny | 2.12 Bn | 1.89 Bn | 89.30 Mn | -32.89 Mn |
| 8 | Surgery Partners | 1.82 Bn | 1.61 Bn | 622.10 Mn | -5.10 Mn |
| 9 | U S Physical Therapy | 1.17 Bn | 1.14 Bn | 41.94 Mn | -31.52 Mn |
| 10 | Starling Oncology | 4.13 Mn | -36.96 Mn | 27.17 Mn | -218,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -218,000.00 |
| Mar 31, 2026 | -28,000.00 |
| Dec 31, 2025 | 3.73 Mn |
| Sep 30, 2025 | 10.60 Mn |
| Jun 30, 2025 | 1.96 Mn |
| Mar 31, 2025 | -4.74 Mn |
| Dec 31, 2024 | -164,000.00 |
| Sep 30, 2024 | -243,000.00 |
| Jun 30, 2024 | -2.15 Mn |
| Mar 31, 2024 | -938,000.00 |
| Dec 31, 2023 | -1.78 Mn |
| Sep 30, 2023 | -756,000.00 |
| Jun 30, 2023 | -2.60 Mn |
| Mar 31, 2023 | -1.71 Mn |
| Dec 31, 2022 | -847,000.00 |
| Sep 30, 2022 | 105.40 Mn |
| Jun 30, 2022 | -10.69 Mn |
| Mar 31, 2022 | -1.66 Mn |
| Dec 31, 2021 | 136.13 Mn |
| Sep 30, 2021 | -8,000.00 |